 |
27 Products |  |
14 Diseases | | 27 Products |
|
13 Trials |  |
837 News |  |
| «123456789 |
- ||| INO-5150 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
New P1 trial, Combination therapy: Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer (clinicaltrials.gov) - Aug 3, 2015
P1, N=60, Recruiting, Sponsor: Inovio Pharmaceuticals
- ||||| MEDI0457 / AstraZeneca
New P2 trial, Combination therapy, Metastases: A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer (clinicaltrials.gov) - Jul 17, 2015
P2, N=126, Not yet recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- ||| rocakinogene sifuplasmid (INO-9012) / Inovio, INO-4201 / Inovio
New P1 trial: Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers (clinicaltrials.gov) - Jun 6, 2015
P1, N=75, Recruiting, Sponsor: Inovio Pharmaceuticals
- ||| INO-1800 / Inovio, INO-9112 / Inovio
New P1 trial, P1 data, Combination therapy: Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects (clinicaltrials.gov) - May 1, 2015
P1, N=126, Recruiting, Sponsor: Inovio Pharmaceuticals
- PENNVAX-GP (HIV DNA vaccine) / Inovio
New P1 trial: Evaluating the Safety and Immunogenicity of PENNVAX (clinicaltrials.gov) - May 1, 2015
P1, N=94, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- | INO-8000 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
New P1/2 trial: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Apr 17, 2015
P1/2, N=116, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | VGX-3400X / GeneOne, Inovio
Trial completion: Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males (clinicaltrials.gov) - Mar 17, 2015
P1, N=30, Completed, Sponsor: GeneOne Life Science, Inc.
Enrolling by invitation --> Completed
- INO-8000 / Inovio
Enrollment closed: VGX-6150-01: Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection (clinicaltrials.gov) - Mar 14, 2015
P1, N=18, Active, not recruiting, Sponsor: GeneOne Life Science, Inc.
Enrolling by invitation --> Completed Recruiting --> Active, not recruiting
- rocakinogene sifuplasmid (INO-9012) / Inovio, INO-1400 / Inovio
New P1 trial, Combination therapy, Surgery: Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers (clinicaltrials.gov) - Dec 30, 2014
P1, N=54, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- rocakinogene sifuplasmid (INO-9012) / Inovio, INO-3106 / Inovio
New P1 trial: Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies (clinicaltrials.gov) - Sep 16, 2014
P1, N=6, Recruiting, Sponsor: Inovio Pharmaceuticals
- | MEDI0457 / AstraZeneca
New P1/2 trial: A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer (clinicaltrials.gov) - Jun 26, 2014
P1/2, N=20, Recruiting, Sponsor: Inovio Pharmaceuticals
- | MEDI0457 / AstraZeneca
Enrollment open, New P1/2 trial: A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer (clinicaltrials.gov) - Jun 26, 2014
P1/2, N=20, Recruiting, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- MEDI0457 / AstraZeneca
Phase classification: Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jun 19, 2014
P1/2, N=20, Recruiting, Sponsor: Inovio Pharmaceuticals
Not yet recruiting --> Recruiting Phase classification: P1 --> P1/2
- | MEDI0457 / AstraZeneca
New P1/2 trial: Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jun 19, 2014
P1/2, N=20, Recruiting, Sponsor: Inovio Pharmaceuticals
- | MEDI0457 / AstraZeneca
Enrollment open, Phase classification: Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jun 19, 2014
P1/2, N=20, Recruiting, Sponsor: Inovio Pharmaceuticals
Phase classification: P1 --> P1/2 Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2
- | MEDI0457 / AstraZeneca
New P1 trial, New P1/2 trial: Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jun 13, 2014
P1, N=20, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- INO-8000 / Inovio
Enrollment open: VGX-6150-01: Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection (clinicaltrials.gov) - Jan 15, 2014
P1, N=18, Recruiting, Sponsor: VGX International, Inc.
Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2 Not yet recruiting --> Recruiting
- | INO-8000 / Inovio
New P1 trial: VGX-6150-01: Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection (clinicaltrials.gov) - Jan 1, 2014
P1, N=18, Recruiting, Sponsor: VGX International, Inc.
- Trial suspension: WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation (clinicaltrials.gov) - Dec 10, 2013
P2, N=184, Suspended, Sponsor: University Hospital Southampton NHS Foundation Trust.
Not yet recruiting --> Recruiting Recruiting --> Suspended
- ||| bizalimogene ralaplasmid (VGX-3100) / Inovio
Enrollment closed, Biopsy: A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 (clinicaltrials.gov) - Sep 18, 2013
P2, N=148, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Recruiting --> Suspended Recruiting --> Active, not recruiting
- PENNVAX-G / Inovio
Enrollment closed: Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults (clinicaltrials.gov) - Jan 23, 2013
P1, N=92, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | PENNVAX-B (HIV clade B DNA vaccine) / Inovio
Trial completion: HIV-001: Study of PENNVAX (clinicaltrials.gov) - Nov 7, 2012
P1, N=12, Completed, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- VGX-3400X / GeneOne, Inovio
Enrollment change: A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001 (clinicaltrials.gov) - Oct 25, 2012
P1, N=22, Completed, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Completed N=30 --> 22
- | VGX-3400X / GeneOne, Inovio
Trial completion: A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001 (clinicaltrials.gov) - Oct 25, 2012
P1, N=22, Completed, Sponsor: Inovio Pharmaceuticals
N=30 --> 22 Active, not recruiting --> Completed
- | VGX-3400X / GeneOne, Inovio
Trial completion: Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults (clinicaltrials.gov) - May 20, 2012
P1, N=32, Completed, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- bizalimogene ralaplasmid (VGX-3100) / Inovio
Enrollment change: Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100 (clinicaltrials.gov) - Dec 8, 2011
P1, N=14, Completed, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Completed N=18 --> 14
- | bizalimogene ralaplasmid (VGX-3100) / Inovio
Trial completion: Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100 (clinicaltrials.gov) - Dec 8, 2011
P1, N=14, Completed, Sponsor: Inovio Pharmaceuticals
N=18 --> 14 Active, not recruiting --> Completed